Zogenix to Participate in the Global Mizuho Investor Conference 2017

EMERYVILLE, Calif., Nov. 29, 2017 (GLOBE NEWSWIRE) -- Zogenix, Inc. ZGNX, a pharmaceutical company developing therapies for the treatment of rare central nervous system (CNS) disorders, today announced that Stephen J. Farr, Ph.D., President and CEO, and Michael P. Smith, Executive Vice President, Chief Financial Officer & Treasurer and Secretary, will conduct investor meetings at the Global Mizuho Investor Conference 2017, taking place December 4-5, 2017, at the Lotte New York Palace Hotel in New York City.  The Company's meetings at the conference will be held on December 5.

About Zogenix

Zogenix, Inc. ZGNX is a pharmaceutical company committed to developing and commercializing CNS therapies that address specific clinical needs for people living with orphan and other CNS disorders who need innovative treatment alternatives to improve their daily functioning.

For more information, visit www.zogenix.com.

CONTACT:     Investors: Andrew McDonald

Founding Partner, LifeSci Advisors LLC

646-597-6987 | Andrew@lifesciadvisors.com